Advertisement
UK markets close in 27 minutes

  • FTSE 100

    8,307.10
    +93.61 (+1.14%)
     

  • FTSE 250

    20,371.94
    +207.40 (+1.03%)
     

  • AIM

    775.72
    +4.19 (+0.54%)
     

  • GBP/EUR

    1.1644
    -0.0016 (-0.14%)
     

  • GBP/USD

    1.2553
    -0.0011 (-0.09%)
     

  • Bitcoin GBP

    51,095.91
    +787.33 (+1.57%)
     

  • CMC Crypto 200

    1,315.48
    -49.64 (-3.64%)
     

  • S&P 500

    5,195.47
    +14.73 (+0.28%)
     

  • DOW

    38,958.24
    +105.97 (+0.27%)
     

  • CRUDE OIL

    77.96
    -0.52 (-0.66%)
     

  • GOLD FUTURES

    2,328.40
    -2.80 (-0.12%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • DAX

    18,402.45
    +227.24 (+1.25%)
     

  • CAC 40

    8,064.81
    +68.17 (+0.85%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

BUZZ-AstraZeneca, Shire: drug competition fears knock shares

Reuters - UK Focus

** AstraZeneca (Swiss: AZN.SW - news) & Shire top UK blue-chip fallers, both down >2 pct, with analysts pointing to concerns over competitive positions of their respective drugs

** Astra hit by worries for sales of diabetes drug Onglyza after Merck (Other OTC: MKGAF - news) 's rival product Januvia shows clean bill of health in heart safety trial, with no increase in hospitalization for heart failure

** Earlier this month, US advisers said Onglyza & Takeda's Nesina had acceptable cardiovascular risk profiles but should carry information labels warning about heart failure risks

** US FDA decision to speed up review of Sanofi (NasdaqGM: GCVRZ - news) 's drug application for a new Fabry disease treatment is cited by one analyst as a possible negative for Shire (Xetra: S7E.DE - news) , given it would be a competitor for the co

ADVERTISEMENT

** Astra shares hit 2.5-wk lows, while Shire falls to 1-wk lows; GlaxoSmithKline (Other OTC: GLAXF - news) also under pressure, with sentiment in the sector also impacted by weakness from US peers

** Healthcare shares were some of US market's worst performers Monday after negative drug development news, reports criticizing high drug prices & a merger setback (RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net; RM: ben.hirschler.thomsonreuters.com@reuters.net)